Health Condition 1: G400- Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset
Conditions
Interventions
Intervention1: Brivaracetam Tablets: Dose: Brivaracetam 25 mg, 50 mg, 100 mg, 200 mg oral tablets.
Frequency: Will be determined by treating investigator.
The tablets will be administered orally and
Sponsors
Torrent Pharmaceuticals Ltd.
Eligibility
Inclusion criteria
Inclusion criteria: 1) Male or female patients with partial onset seizures with or without secondary generalization in patients 18 years of age and older with epilepsy. 2) Known cases brivaracetam receiving therapy for more than equal to 2 weeks.
Exclusion criteria
Exclusion criteria: Patients allergic to brivaracetam or any of the ingredients in medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Seizure FrequencyTimepoint: 4 weeks and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinicians Global Impression – Efficacy Index (CGI-EI)Timepoint: 4 weeks and 12 weeks;Demographic patternTimepoint: Baseline;Other Anti-epileptic drugs (AEDs) used along with BRV.Timepoint: Baseline, 4 weeks and 12 weeks;Patient’s treatment acceptabilityTimepoint: 4 weeks and 12 weeks;Prevalence of other co-morbid conditions along with Focal EpilepsyTimepoint: Baseline;Quality of lifeTimepoint: 4 weeks and 12 weeks;Responders RateTimepoint: 4 weeks and 12 weeks;Safety assessments in terms of AEsTimepoint: 4 weeks and 12 weeks;Seizure FreedomTimepoint: 4 weeks and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Krishnaprasad K
Karunesh Neuro and Spine SUrgical Hospital
Outcome results
None listed